Overview
Dr. Somasundaram Subramaniam is a Medical Oncologist at the Swedish Cancer Institute in Seattle, Washington and a 2021 Seattle Met Top Doctor Award winner. He has specialized expertise in the management of Gastrointestinal (GI) Cancers. This includes common cancers like colon and rectal cancers and also less common cancers like stomach cancer, neuroendocrine tumors (NETs) and liver and bile duct cancers. He also treats patients with lung cancer and kidney cancer. Dr. Soma chose to pursue a career in Oncology to help patients diagnosed with very serious illnesses and their families by providing hope, education and the best opportunities for treatment and cure. He is thrilled to be working with at Swedish, which has an excellent group of caring and highly-trained physicians, nurses and providers who all work very closely together with a robust multi-disciplinary team approach.. Dr. Subramaniam is an investigator on several clinical trials and a key member of the Personalized Medicine Research Program at Swedish, which focuses on the using a tumor’s DNA mutations to target it with newer drugs. The Swedish Cancer Institute prioritizes opening cutting-edge clinical trials to ensure patients have access to the latest innovations in cancer therapy. Dr. Subramaniam graduated from medical school at the National University of Singapore and obtained sub-specialty training during his fellowship at Stanford University, which was supported by a T32 training grant awarded by the National Institutes of Health. He is board-certified in Internal Medicine and Medical Oncology. Dr. Subramaniam also earned a Master of Science degree in Epidemiology and Clinical Research from Stanford. In addition to treating patients with cancer, Dr. Subramaniam is the Medical Director of the Cancer Control program, which emphasizes preventative measures and appropriate cancer screening, to reduce the incidence and burden of cancer in our community.
Dr. Subramaniam is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Colorectal Cancer, Nerve Decompression, and Endoscopy.
His clinical research consists of co-authoring 21 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- MANAGED MEDICAID PLAN
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- PPO
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- EPO
- PPO
- EPO
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1221 Madison Street, 0, Seattle, WA 98104
500 17th Avenue, Seattle, WA 98122
747 Broadway, Seattle, WA 98122
Additional Areas of Focus
Dr. Subramaniam has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Medical Oncology - Swedish Cancer Institute First Hill
Cancer is a terrible disease—often one of the most frightening and uncertain experiences a person can face. My philosophy is to approach every patient with a blend of deep empathy and evidence-based treatment options, empowering them to make informed decisions that align with their values, needs, and goals. I believe that compassionate care and scientific rigor form the foundation of meaningful, personalized cancer care. Dr. Santana is rated as a Distinguished provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.
Bernardo Goulart is an Oncologist in Seattle, Washington. Dr. Goulart is rated as a Distinguished provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Metastatic Pleural Tumor. Dr. Goulart is currently accepting new patients.
Franciscan Oncology At St. Joseph
"Joseph Rosales, MD, has been a physician for over 20 years and a hematologist-oncologist in Western Washington since 2011 -- in Seattle, Federal Way and Tacoma. He is experienced in general hematology and oncology, with specialties in breast and thoracic oncology. Dr. Rosales considers himself a guide in his patients’ therapeutic journey. He meets his patients wherever they are - physically and emotionally - and strives to provide them the knowledge and perspective required to navigate difficult decisions in their care. His treatment philosophy has been consistent: to make sure that the patient remains in as much control of their care as possible while getting the best care possible.Dr. Rosales also maintains activity within the community, including involvement in oncologic education and advocacy. He received the2022 Binaytara Foundation for Excellence in Cancer Care ""Rising Star in Health Equity"" awardfor his demonstration of excellent leadership in improving cancer care in underprivileged communities.Multidisciplinary Lung Cancer Treatment during Covid-19 Video". Dr. Rosales is rated as a Distinguished provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Bone Marrow Aspiration.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- ALK-Positive Non-Small Cell Lung CancerDr. Subramaniam isDistinguished. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- Anal CancerDr. Subramaniam isDistinguished. Learn about Anal Cancer.
- Cholangiocarcinoma (Bile Duct Cancer)Dr. Subramaniam isDistinguished. Learn about Cholangiocarcinoma (Bile Duct Cancer).
- Colorectal CancerDr. Subramaniam isDistinguished. Learn about Colorectal Cancer.
- Familial Colorectal CancerDr. Subramaniam isDistinguished. Learn about Familial Colorectal Cancer.
- Familial Pancreatic CancerDr. Subramaniam isDistinguished. Learn about Familial Pancreatic Cancer.
- Advanced
- Ampullary CancerDr. Subramaniam isAdvanced. Learn about Ampullary Cancer.
- EGFR Positive Lung CancerDr. Subramaniam isAdvanced. Learn about EGFR Positive Lung Cancer.
- Gallbladder AdenocarcinomaDr. Subramaniam isAdvanced. Learn about Gallbladder Adenocarcinoma.
- Gallbladder CancerDr. Subramaniam isAdvanced. Learn about Gallbladder Cancer.
- Large-Cell Lung CarcinomaDr. Subramaniam isAdvanced. Learn about Large-Cell Lung Carcinoma.
- Lung CancerDr. Subramaniam isAdvanced. Learn about Lung Cancer.
- Experienced
- Adult Soft Tissue SarcomaDr. Subramaniam isExperienced. Learn about Adult Soft Tissue Sarcoma.
- Appendix CancerDr. Subramaniam isExperienced. Learn about Appendix Cancer.
- Carcinoid SyndromeDr. Subramaniam isExperienced. Learn about Carcinoid Syndrome.
- Childhood Acute Myeloid LeukemiaDr. Subramaniam isExperienced. Learn about Childhood Acute Myeloid Leukemia.
- ChondrosarcomaDr. Subramaniam isExperienced. Learn about Chondrosarcoma.
- Chromophobe Renal Cell CarcinomaDr. Subramaniam isExperienced. Learn about Chromophobe Renal Cell Carcinoma.